Biosimilar to reference denosumab. Inhibits osteoclast activity for osteoporosis and bone loss prevention in postmenopausal women and cancer patients.
Binds RANKL (receptor activator of nuclear factor kappa-B ligand) preventing interaction with RANK receptor on osteoclast precursors and mature osteoclasts, inhibiting osteoclast formation, function, and survival.
Binds RANKL (receptor activator of nuclear factor kappa-B ligand) preventing interaction with RANK receptor on osteoclast precursors and mature osteoclasts, inhibiting osteoclast formation, function, and survival.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
